Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Reeder CB"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-17 z 17
    Tytuł:
    Insurance-based disparities impact survival outcomes in Waldenström macroglobulinemia within the United States.
    Autorzy:
    Chohan KL; Department of Medicine, Mayo Clinic, Rochester, MN, USA.
    Abeykoon JP; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
    Ansell SM; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
    Gertz MA; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
    Kapoor P; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
    Paulus A; Division of Hematology, Mayo Clinic, Jacksonville, FL, USA.
    Ailawadhi S; Division of Hematology, Mayo Clinic, Jacksonville, FL, USA.
    Reeder CB; Division of Hematology, Mayo Clinic, Phoenix, AZ, USA.
    Witzig TE; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
    Habermann TM; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
    Lacy MQ; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
    Kyle RA; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
    Go RS; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
    Paludo J; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2022 Dec; Vol. 63 (12), pp. 2879-2888. Date of Electronic Publication: 2022 Jul 23.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Medicare*
    Waldenstrom Macroglobulinemia*
    United States/epidemiology ; Humans ; Male ; Aged ; Middle Aged ; Insurance Coverage ; Medically Uninsured ; Medicaid ; Healthcare Disparities ; Insurance, Health
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia.
    Autorzy:
    Gunaratne MDSK; Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
    Sahakian AJ; Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
    Abeykoon JP; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
    Ansell SM; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
    Gertz MA; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
    Kapoor P; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
    Paulus A; Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.
    Ailawadhi S; Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.
    Reeder CB; Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA.
    Witzig TE; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
    Habermann TM; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
    Novak AJ; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
    Lacy MQ; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
    Kyle RA; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
    Go RS; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
    Paludo J; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2021 Feb; Vol. 62 (2), pp. 308-315. Date of Electronic Publication: 2020 Oct 15.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Waldenstrom Macroglobulinemia*/diagnosis
    Waldenstrom Macroglobulinemia*/epidemiology
    Waldenstrom Macroglobulinemia*/therapy
    Databases, Factual ; Humans ; Incidence ; Risk Factors
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma.
    Autorzy:
    Sonbol MB; a Division of Hematology/Oncology , Mayo Clinic , Phoenix , AZ , USA.
    Hilal T; a Division of Hematology/Oncology , Mayo Clinic , Phoenix , AZ , USA.
    Dueck AC; b Section of Biostatistics , Mayo Clinic , Scottsdale , AZ , USA.
    Rosenthal AC; a Division of Hematology/Oncology , Mayo Clinic , Phoenix , AZ , USA.
    Conley CR; c Department of Laboratory Medicine and Pathology , Mayo Clinic , Scottsdale , AZ , USA.
    Kosiorek HE; b Section of Biostatistics , Mayo Clinic , Scottsdale , AZ , USA.
    Ginos BF; b Section of Biostatistics , Mayo Clinic , Scottsdale , AZ , USA.
    Gano KM; d Cancer Clinical Research Office, Mayo Clinic , Phoenix , AZ , USA.
    Nichols CS; e Division of Hematology , Mayo Clinic , Rochester , MN , USA.
    Leis JF; a Division of Hematology/Oncology , Mayo Clinic , Phoenix , AZ , USA.
    Johnston PB; e Division of Hematology , Mayo Clinic , Rochester , MN , USA.
    Habermann TM; e Division of Hematology , Mayo Clinic , Rochester , MN , USA.
    Northfelt DW; a Division of Hematology/Oncology , Mayo Clinic , Phoenix , AZ , USA.
    Bergsagel PL; a Division of Hematology/Oncology , Mayo Clinic , Phoenix , AZ , USA.
    Inwards DJ; e Division of Hematology , Mayo Clinic , Rochester , MN , USA.
    Witzig TE; e Division of Hematology , Mayo Clinic , Rochester , MN , USA.
    Ansell SM; e Division of Hematology , Mayo Clinic , Rochester , MN , USA.
    Reeder CB; a Division of Hematology/Oncology , Mayo Clinic , Phoenix , AZ , USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2018 Sep; Vol. 59 (9), pp. 2128-2134. Date of Electronic Publication: 2018 Jan 10.
    Typ publikacji:
    Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Lymphoma, Mantle-Cell/*drug therapy
    Aged ; Aged, 80 and over ; Anemia/chemically induced ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib/administration & dosage ; Bortezomib/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Fatigue/chemically induced ; Female ; Humans ; Lymphoma, Mantle-Cell/pathology ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Recurrence, Local ; Rituximab/administration & dosage ; Rituximab/adverse effects ; Survival Analysis ; Thrombocytopenia/chemically induced
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Ibrutinib-induced acute liver failure.
    Autorzy:
    Kahn A; a Division of Gastroenterology and Hepatology , Mayo Clinic , Phoenix , AZ , USA.
    Horsley-Silva JL; a Division of Gastroenterology and Hepatology , Mayo Clinic , Phoenix , AZ , USA.
    Lam-Himlin DM; b Department of Laboratory Medicine and Pathology , Mayo Clinic , Phoenix , AZ , USA.
    Reeder CB; c Division of Hematology and Oncology , Mayo Clinic , Phoenix , AZ , USA.
    Douglas DD; a Division of Gastroenterology and Hepatology , Mayo Clinic , Phoenix , AZ , USA.
    Carey EJ; a Division of Gastroenterology and Hepatology , Mayo Clinic , Phoenix , AZ , USA.
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2018 Feb; Vol. 59 (2), pp. 512-514. Date of Electronic Publication: 2017 Jul 11.
    Typ publikacji:
    Case Reports; Letter
    MeSH Terms:
    Liver Failure, Acute/*diagnosis
    Liver Failure, Acute/*etiology
    Protein Kinase Inhibitors/*adverse effects
    Pyrazoles/*adverse effects
    Pyrimidines/*adverse effects
    Adenine/analogs & derivatives ; Biomarkers ; Combined Modality Therapy ; Female ; Humans ; Liver Failure, Acute/therapy ; Middle Aged ; Piperidines ; Protein Kinase Inhibitors/therapeutic use ; Pyrazoles/therapeutic use ; Pyrimidines/therapeutic use ; Treatment Outcome ; Waldenstrom Macroglobulinemia/complications ; Waldenstrom Macroglobulinemia/drug therapy
    Raport
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).
    Autorzy:
    Wang M; Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, USA. .
    Schuster SJ; Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA.
    Phillips T; University of Michigan, Ann Arbor, MI, USA.
    Lossos IS; Sylvester Comprehensive Cancer Center, Division of Hematology Oncology, University of Miami, Miami, FL, USA.
    Goy A; John Theurer Cancer Center at HUMC, Hackensack, NJ, USA.
    Rule S; Department of Haematology, Derriford Hospital and Plymouth University Medical School, Plymouth, UK.
    Hamadani M; Medical College of Wisconsin & CIBMTR, Milwaukee, WI, USA.
    Ghosh N; Carolinas HealthCare System, Levine Cancer Institute, Charlotte, NC, USA.
    Reeder CB; Mayo Clinic Scottsdale/Phoenix, Scottsdale, AZ, USA.
    Barnett E; Celgene Corporation, Summit, NJ, USA.
    Bravo MC; Celgene International Sàrl, Boudry, Switzerland.
    Martin P; Weill Cornell Medical College, New York, NY, USA.
    Pokaż więcej
    Źródło:
    Journal of hematology & oncology [J Hematol Oncol] 2017 Nov 02; Vol. 10 (1), pp. 171. Date of Electronic Publication: 2017 Nov 02.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Lymphoma, Mantle-Cell/*drug therapy
    Pyrazoles/*therapeutic use
    Pyrimidines/*therapeutic use
    Thalidomide/*analogs & derivatives
    Adenine/analogs & derivatives ; Aged ; Aged, 80 and over ; Disease Progression ; Female ; Humans ; Lenalidomide ; Lymphoma, Mantle-Cell/pathology ; Male ; Middle Aged ; Piperidines ; Pyrazoles/pharmacology ; Pyrimidines/pharmacology ; Recurrence ; Thalidomide/pharmacology ; Thalidomide/therapeutic use
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma.
    Autorzy:
    Witzig TE; Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN, USA.
    Laumann KM
    Lacy MQ
    Hayman SR
    Dispenzieri A
    Kumar S
    Reeder CB
    Roy V
    Lust JA
    Gertz MA
    Greipp PR
    Hassoun H
    Mandrekar SJ
    Rajkumar SV
    Pokaż więcej
    Źródło:
    Leukemia [Leukemia] 2013 Jan; Vol. 27 (1), pp. 220-5. Date of Electronic Publication: 2012 Aug 20.
    Typ publikacji:
    Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Bone Density Conservation Agents/*therapeutic use
    Diphosphonates/*therapeutic use
    Imidazoles/*therapeutic use
    Immunosuppressive Agents/*therapeutic use
    Multiple Myeloma/*drug therapy
    Thalidomide/*therapeutic use
    Aged ; Aged, 80 and over ; Disease Progression ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Multiple Myeloma/mortality ; Multiple Myeloma/pathology ; Neoplasm Staging ; Prognosis ; Survival Rate ; Zoledronic Acid
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique.
    Autorzy:
    Gertz MA; Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA. />Reeder CB
    Kyle RA
    Ansell SM
    Pokaż więcej
    Źródło:
    Bone marrow transplantation [Bone Marrow Transplant] 2012 Sep; Vol. 47 (9), pp. 1147-53. Date of Electronic Publication: 2011 Aug 29.
    Typ publikacji:
    Journal Article; Review
    MeSH Terms:
    Stem Cell Transplantation/*methods
    Waldenstrom Macroglobulinemia/*surgery
    Humans ; Transplantation, Autologous
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Histologic remission of cardiac amyloidosis: a case report.
    Autorzy:
    Nelson MR; Division of Cardiovascular Diseases, Mayo Clinic Scottsdale, Arizona, USA.
    Lanza LA
    Reeder CB
    Scott RL
    McCullough AE
    Chandrasekaran K
    Click RL
    Pokaż więcej
    Źródło:
    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis [Amyloid] 2012 Jun; Vol. 19 (2), pp. 106-9. Date of Electronic Publication: 2012 Mar 07.
    Typ publikacji:
    Case Reports; Journal Article
    MeSH Terms:
    Amyloidosis/*diagnostic imaging
    Cardiomyopathies/*diagnostic imaging
    Amyloid/metabolism ; Amyloidosis/drug therapy ; Amyloidosis/metabolism ; Cardiomyopathies/drug therapy ; Cardiomyopathies/metabolism ; Humans ; Male ; Middle Aged ; Remission Induction ; Tretoquinol ; Ultrasonography
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.
    Autorzy:
    Nowakowski GS; Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA. />LaPlant B
    Habermann TM
    Rivera CE
    Macon WR
    Inwards DJ
    Micallef IN
    Johnston PB
    Porrata LF
    Ansell SM
    Klebig RR
    Reeder CB
    Witzig TE
    Pokaż więcej
    Źródło:
    Leukemia [Leukemia] 2011 Dec; Vol. 25 (12), pp. 1877-81. Date of Electronic Publication: 2011 Jul 01.
    Typ publikacji:
    Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Lymphoma, Follicular/*drug therapy
    Lymphoma, Large B-Cell, Diffuse/*drug therapy
    Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Murine-Derived/administration & dosage ; Cyclophosphamide/administration & dosage ; Doxorubicin/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Lenalidomide ; Lymphoma, Follicular/mortality ; Lymphoma, Follicular/pathology ; Lymphoma, Large B-Cell, Diffuse/mortality ; Lymphoma, Large B-Cell, Diffuse/pathology ; Male ; Maximum Tolerated Dose ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/pathology ; Neoplasm Staging ; Prednisone/administration & dosage ; Rituximab ; Survival Rate ; Thalidomide/administration & dosage ; Thalidomide/analogs & derivatives ; Treatment Outcome ; Vincristine/administration & dosage
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma.
    Autorzy:
    Witzig TE; Division of Hematology, Department of Medicine, Mayo Clinic College of Medicine and Mayo Foundation, Rochester, MN 55905, USA. />Reeder CB
    LaPlant BR
    Gupta M
    Johnston PB
    Micallef IN
    Porrata LF
    Ansell SM
    Colgan JP
    Jacobsen ED
    Ghobrial IM
    Habermann TM
    Pokaż więcej
    Źródło:
    Leukemia [Leukemia] 2011 Feb; Vol. 25 (2), pp. 341-7. Date of Electronic Publication: 2010 Dec 07.
    Typ publikacji:
    Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Lymphoma, Non-Hodgkin/*drug therapy
    Protein Kinase Inhibitors/*therapeutic use
    Salvage Therapy/*methods
    Sirolimus/*analogs & derivatives
    TOR Serine-Threonine Kinases/*antagonists & inhibitors
    Administration, Oral ; Adult ; Aged ; Aged, 80 and over ; Everolimus ; Female ; Humans ; Lymphoma, Non-Hodgkin/complications ; Male ; Middle Aged ; Remission Induction ; Sirolimus/administration & dosage ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.
    Autorzy:
    Reeder CB; Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA. Reeder. />Reece DE
    Kukreti V
    Chen C
    Trudel S
    Hentz J
    Noble B
    Pirooz NA
    Spong JE
    Piza JG
    Zepeda VH
    Mikhael JR
    Leis JF
    Bergsagel PL
    Fonseca R
    Stewart AK
    Pokaż więcej
    Źródło:
    Leukemia [Leukemia] 2009 Jul; Vol. 23 (7), pp. 1337-41. Date of Electronic Publication: 2009 Feb 19.
    Typ publikacji:
    Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Multiple Myeloma/*drug therapy
    Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Boronic Acids/administration & dosage ; Bortezomib ; Cyclophosphamide/administration & dosage ; Dexamethasone/administration & dosage ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/surgery ; Pyrazines/administration & dosage ; Stem Cell Transplantation ; Treatment Outcome
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group.
    Autorzy:
    Witzig TE; Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA. />Geyer SM
    Kurtin PJ
    Colgan JP
    Inwards DJ
    Micallef IN
    LaPlant BR
    Michalak JC
    Salim M
    Dalton RJ
    Moore DF Jr
    Reeder CB
    Pokaż więcej
    Corporate Authors:
    North Central Cancer Treatment Group
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 2008 Jun; Vol. 49 (6), pp. 1074-80.
    Typ publikacji:
    Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
    MeSH Terms:
    Antibodies, Monoclonal/*therapeutic use
    Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
    Lymphoma, Non-Hodgkin/*drug therapy
    Neoplasm Recurrence, Local/*drug therapy
    Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Murine-Derived ; Cisplatin/therapeutic use ; Cytarabine/therapeutic use ; Dexamethasone/therapeutic use ; Female ; Humans ; Lymphoma, B-Cell, Marginal Zone/drug therapy ; Lymphoma, Follicular/drug therapy ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Lymphoma, Mantle-Cell/drug therapy ; Male ; Maximum Tolerated Dose ; Middle Aged ; Prognosis ; Rituximab ; Salvage Therapy ; Treatment Outcome
    SCR Protocol:
    DHAP protocol
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy.
    Autorzy:
    Stewart AK; Department of Medicine, Division of Hematology-Oncology, Mayo Clinic College of Medicine, Scottsdale, AZ 85259, USA. />Bergsagel PL
    Greipp PR
    Dispenzieri A
    Gertz MA
    Hayman SR
    Kumar S
    Lacy MQ
    Lust JA
    Russell SJ
    Witzig TE
    Zeldenrust SR
    Dingli D
    Reeder CB
    Roy V
    Kyle RA
    Rajkumar SV
    Fonseca R
    Pokaż więcej
    Źródło:
    Leukemia [Leukemia] 2007 Mar; Vol. 21 (3), pp. 529-34. Date of Electronic Publication: 2007 Jan 18.
    Typ publikacji:
    Journal Article
    MeSH Terms:
    Clinical Trials as Topic/*standards
    Multiple Myeloma/*classification
    Antineoplastic Agents/therapeutic use ; Chromosomes, Human/genetics ; Chromosomes, Human/ultrastructure ; Counseling ; Decision Making ; Diagnostic Tests, Routine ; Drug Design ; Gene Targeting ; Genetic Therapy ; Genotype ; Humans ; Multiple Myeloma/genetics ; Multiple Myeloma/therapy ; Plasma Cells/pathology ; Prognosis ; Risk ; Risk Assessment ; Translocation, Genetic ; Treatment Outcome ; Tumor Burden
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia.
    Autorzy:
    Tefferi A; Mayo Clinic, Rochester, MN 55905, USA.
    Li CY
    Reeder CB
    Geyer SM
    Allmer C
    Levitt R
    Michalak JC
    Addo F
    Krook JE
    Witzig TE
    Schaefer PL
    Mailliard JA
    Pokaż więcej
    Źródło:
    Leukemia [Leukemia] 2001 Aug; Vol. 15 (8), pp. 1171-5.
    Typ publikacji:
    Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S.
    MeSH Terms:
    Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
    Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
    Adult ; Aged ; Cladribine/administration & dosage ; Cyclophosphamide/administration & dosage ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/mortality ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Male ; Middle Aged ; Prednisone/administration & dosage ; Remission Induction
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    CD5+ persistent polyclonal B-cell lymphocytosis in a male.
    Autorzy:
    Reeder CB; Department of Laboratory Medicine and Pathology, Mayo Clinic Scottsdale, Arizona 85259, USA.
    Conley CR
    Pokaż więcej
    Źródło:
    Leukemia & lymphoma [Leuk Lymphoma] 1999 May; Vol. 33 (5-6), pp. 593-6.
    Typ publikacji:
    Case Reports; Journal Article
    MeSH Terms:
    Lymphocytosis*
    B-Lymphocytes/*pathology
    Adult ; B-Lymphocytes/immunology ; CD5 Antigens ; Cell Differentiation ; Female ; Humans ; Lymphoproliferative Disorders/immunology ; Lymphoproliferative Disorders/pathology ; Male
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
      Wyświetlanie 1-17 z 17

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies